Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2

Phase 3

Terminated

Conditions: Urinary Incontinence
Overactive Bladder

Interventions: Biological: Botulinum toxin type A
Drug: Placebo

Registration Number: NCT02660359

Lead Sponsor: Ipsen

Brief Summary: The purpose of this study is to provide confirmatory evidence of the safety and efficacy of two Dysport® doses (600 units \[U\] and 800 U), compared to placebo in reducing urinary incontinence (UI) in adult subjects treated for neurogenic detrusor overactivity (NDO) due to spinal cord injury (SCI) or multiple sclerosis (MS).

Detailed Description: Not available

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 258

Inclusion Criteria

Urinary Incontinence for at least 3 months prior to Screening as a result of Neurogenic Detrusor Overactivity due to Spinal Cord Injury or Multiple Sclerosis.
Subjects with Spinal Cord Injury must have a stable neurological injury at T1 level or below which occurred at least 6 months prior to Screening.
Subjects with Multiple Sclerosis must be clinically stable in the investigator's opinion, with no exacerbation (relapse) of MS for at least 3 months prior to Screening.
Subjects must have had an inadequate response after at least 4 weeks of oral medications used in the treatment of NDO (e.g. anticholinergics, beta-3 agonists) and/or have intolerable side-effects.
Routinely performing Clean Intermittent Catheterization (CIC) to ensure adequate bladder emptying.
An average of at least two episodes per day of Urinary Incontinence recorded on the screening bladder diary.

Key

Exclusion Criteria

Any current condition (other than NDO) that may impact on bladder function.
Previous or current, tumour or malignancy affecting the spinal column or spinal cord, or any other unstable cause of SCI.
Any condition that will prevent cystoscopic treatment administration or CIC usage, e.g. urethral strictures.
Current indwelling bladder catheter, or removal of indwelling bladder catheter less than 4 weeks prior to Screening.
BTX-A treatment within 9 months prior to Screening for any urological condition (e.g. detrusor or urethral sphincter treatments).
Any neuromodulation/electrostimulation usage for urinary symptoms/incontinence within 4 weeks prior to Screening. Any implanted neuromodulation device must be switched off at least 4 weeks prior to Screening.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
600 U Dysport® Group	Botulinum toxin type A	-
600 U Dysport® Placebo Group	Placebo	-
800 U Dysport® Group	Botulinum toxin type A	-
800 U Dysport® Placebo Group	Placebo	-

Primary Outcome Measures

Name	Time	Method
Mean Change From Baseline in Weekly Number of UI Episodes at Week 6 of DBPC Cycle	Baseline and Week 6 of DBPC Cycle	The weekly number of UI episodes was measured using a 7-day bladder diary. Bladder diaries that contained data recorded on at least 5 days were included in the analysis. The least square (LS) mean of the change in weekly number of UI episodes at 6 weeks after the first study treatment was calculated using a mixed model repeated measures (MMRM) analysis.

Secondary Outcome Measures

Name	Time	Method
Mean Change From Baseline in Maximum Detrusor Pressure (MDP) During Storage at Week 6 of DBPC Cycle	Baseline and Week 6 of DBPC Cycle	Subjects included in the urodynamic subset (84.9% of randomised subjects) had a standardised urodynamic filling cystometry assessment at baseline (Screening) and again at Week 6 to determine the MDP. The LS mean of the change in MDP at 6 weeks after the first study treatment was calculated using an ANCOVA.
Percentage of Subjects With No Episodes of UI at Week 6 of DBPC Cycle	Baseline and Week 6 of DBPC Cycle	The weekly number of UI episodes was measured using a 7-day bladder diary. Bladder diaries that contained data recorded on at least 5 days were included in the analysis. The number of subjects with no UI episodes at 6 weeks after the first study treatment was recorded. Percentage of subjects with no episodes of UI (≥100% Improvement) was calculated as: Total number of subjects with no weekly number of UI episodes at Week 6 / Total number of subjects with any number of UI events at Week 6.
Percentage of Subjects With a UI Response at Improvement Levels ≥30%, ≥50%, and ≥75% at Week 6 of the DBPC Cycle	Baseline and Week 6 of DBPC Cycle	The weekly number of UI episodes was measured using a 7-day bladder diary. Bladder diaries that contained data recorded on at least 5 days were included in the analysis. The percentage of subjects showing an improvement of ≥30%, ≥50% and ≥75% was calculated as: Total number of subjects with UI response level \>=30% or \>=50% or \>=75% improvement at Week 6 / Total number of subjects with any UI response at Week 6.
Mean Change From Baseline in Volume Per Void at Week 6 of DBPC Cycle	Baseline and Week 6 of DBPC Cycle	The volume per void was measured during one 24-hour period of the 7-day bladder diary. The LS mean of the change in volume per void at 6 weeks after the first study treatment was calculated using a MMRM analysis.
Mean Change From Baseline in Volume at First Involuntary Detrusor Contraction (Vol@1stIDC) at Week 6 of DBPC Cycle	Baseline and Week 6 of DBPC Cycle	Subjects included in the urodynamic subset (84.9% of randomised subjects) had a standardised urodynamic filling cystometry assessment at baseline (Screening) and again at Week 6 to determine the Vol@1stIDC which is the instilled volume when first IDC commences. Subjects who did not exhibit a post-treatment IDC at Week 6 had Vol@1stIDC imputed using the recorded corrected MCC volume at Week 6. The LS mean of the change in Vol@1stIDC at 6 weeks after the first study treatment was calculated using an ANCOVA.
Median Time Between Treatments	Day of first treatment (baseline) to day of retreatment, up to 2 years	Duration of effect for time between treatments was calculated by: (the date of the first retreatment visit - date of first treatment administration in the DBPC cycle). The median number of days between treatments was determined and subjects with no retreatment were censored at the last visit.
Mean Change From Baseline in Maximum Cystometric Capacity (MCC) at Week 6 of DBPC Cycle	Baseline and Week 6 of DBPC Cycle	Subjects included in the urodynamic subset (84.9% of randomised subjects) had a standardised urodynamic filling cystometry assessment at baseline (Screening) and again at Week 6 to determine the MCC. The LS mean of the change in MCC at 6 weeks after the first study treatment was calculated using an analysis of covariance (ANCOVA).
Percentage of Subjects With No Involuntary Detrusor Contraction (IDCs) During Storage at Week 6 of DBPC Cycle	Baseline and Week 6 of DBPC Cycle	Subjects included in the urodynamic subset (84.9% of randomised subjects) had a standardised urodynamic filling cystometry assessment at baseline (Screening) and again at Week 6 to determine the occurrence of IDCs. The percentage of subjects without IDCs at 6 weeks after the first study treatment was recorded.

Trial Locations

Locations (82): Instituto Urológico Buenos Aires
🇦🇷
Buenos Aires, Argentina
Centro de Urologia
🇦🇷
Buenos Aires, Argentina
Centro Urológico Profesor Bengió
🇦🇷
Córdoba, Argentina
Hospital Privado - Centro Médico de Córdoba
🇦🇷
Córdoba, Argentina
Instituto Médico Rodriguez Alfici
🇦🇷
Godoy Cruz, Argentina
Prince of Wales Hospital (POWH)
🇦🇺
Sydney, Australia
Westmead Hospital
🇦🇺
Westmead, Australia
Antwerp University hospital
🇧🇪
Antwerp, Belgium
Hôpital Erasme
🇧🇪
Brussels, Belgium
Ourthe-Amblève
🇧🇪
Esneux, Belgium
Scroll for more (72 remaining)
Instituto Urológico Buenos Aires
🇦🇷Buenos Aires, Argentina